Skip to main content

Advertisement

Table 1 Study summary

From: Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

  SATURN [11, 12] ATLAS [13] AVAPERL [14, 15]
Investigational drug Erlotinib Erlotinib Pemetrexed
N: run-in phasea 1949 1145 376
N: maintenance phaseb 889 743 253
N: evaluablec 837 (94 %) 697 (94 %) 231 (94 %)
BTS (cm) 6.99 6.1 5.21
Femaled 26 % 48 % 43 %
ECOG score >0d 69 % 66 % 52 %
Age ≥ 55 yearsd 70 % 77 % 72 %
Asiand 15 % 13 % 12 %
Study number BO18192 AVF3671g MO22089
ClinicalTrials.gov Identifier NCT00556712 NCT00257608 NCT00961415
Trial registration datee Nov 9, 2007 Nov 21, 2005 Aug 18, 2009
Retrospective registration No No No
  1. BTS baseline tumor size at randomization, ECOG Eastern Cooperative Oncology Group, TGI tumor growth inhibition
  2. aNumber of patients who received four cycles of first-line treatment (run-in phase)
  3. bNumber of patients whose disease did not progress during the run-in phase and who were randomized in the maintenance phase
  4. cNumber of evaluable patients, i.e. patients with at least two tumor size measurements in the maintenance phase (at least one tumor size measurement after randomization). The number in the parenthesis represents the percentage of evaluable patients out of the patients randomized
  5. dThe percentage of patients among evaluable patients
  6. eThe date of “First received” as displayed on ClinicalTrials.gov